Dr. Reddy's Laboratories Launches Ramelteon Tablets, in the US Market
23 July 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem (ramelteon, 8 mg) Tablets, approved by the US Food and Drug Administration (USFDA), the company said.
The Rozerem brand had US sales of approximately USD 91.3m MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.
Dr. Reddy's Ramelteon Tablets are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000.
Dr. Reddy's Laboratories is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.
Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.